PCVX实时信号 | 通过Getagraph.com最大化利润

出售 3070 min ago

@ $60.49

发出时间: 27 Apr 2024 @ 01:03

回报率: 0.39%

上一信号: Apr 26 - 23:21

上一信号: 购买

回报率: 1.30 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	583 957
平均成交量	865 760
市值	6.60B
EPS	$0 ( 2024-02-27 )
下一个收益日期	( $-1.110 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.67
ATR14	$1.533 (2.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Pickering Grant	Buy	15 000	Common Stock
2024-04-23	Pickering Grant	Sell	15 000	Common Stock
2024-04-23	Pickering Grant	Sell	15 000	Stock Option (Right to Buy)
2024-04-18	Guggenhime Andrew	Sell	8 000	Stock Option (right to buy)
2024-04-18	Guggenhime Andrew	Buy	8 000	Common Stock

INSIDER POWER
36.03
Last 100 transactions
Buy: 779 468 \| Sell: 362 821

音量相关性

長: -0.43 (neutral)

短: 0.88 (strong)

Signal:(68) Same movement expected

Vaxcyte Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Vaxcyte Inc 相关性 - 货币/商品

0.61
( weak )

0.59
( weak )

0.00
( neutral )

0.47
( neutral )

0.29
( neutral )

-0.57
( weak negative )

Vaxcyte Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2023
营收:	$0
毛利润:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2022
营收:	$0
毛利润:	$-9.20M (0.00 %)
EPS:	$-3.69

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.